title: Development of mouse dendritic cells from lineage-negative c-kit(low) pluripotent hemopoietic stem cells in vitro.
abstract: Dendritic cells (DCs) are essential for the presentation of antigens in the primary immune response. To examine the generation of DCs from hemopoietic stem cells in the bone marrow (BM), lineage-negative (Lin-)/CD71- bone marrow cells (BMCs) from C57BL/6 mice were separated into major histocompatibility complex (MHC) class Ihigh/ c-kit(low) and MHC class Ihigh/c-kit(low)(phenotypically c-kit-negative, but c-kit message only detected by reverse transcriptase-polymerase chain reaction) populations. A large number of cells with the morphological, phenotypical, and functional characteristics of DCs was generated from both c-kit(low) and c-kit(low) populations when cultured with a combination of cytokines (GM-CSF, tumor necrosis factor-a [TNF-a], interleukin 7 [IL-7], IL-3, stem cell factor [SCF], and flt3 ligand); the cytokine combination studies revealed that SCF and IL-3 in addition to GM-CSF and TNF-a are essential for DCs to be generated from these primitive populations. To our surprise most (>80%) generated cells expressed high levels of DC surface markers such as DEC205 and MHC class II, and they were potent stimulators in the primary allogeneic T cell activation. The development of DCs from c-kit(<low) cells was slower than that from c-kit(low) cells. These results indicate that c-kit(<low) cells are more primitive than c-kit(low) cells, although both c-kit*(low) cells and c-kit(<low) cells can differentiate into DCs. It should be noted that the combination of these cytokines selectively induces DCs from both c-kit(<low) and c-kit(low) cells in vitro, suggesting that the ex vivo expansion of DCs using these primitive cells would be applicable to immunotherapy.
authors.affiliation: First Department of Pathology, Kansai Medical University, Moriguchi City, Osaka, Japan.
authors.forename: B
authors.initials: B
authors.lastname: Feng
authors.forename: M
authors.initials: M
authors.lastname: Inaba
authors.forename: Z
authors.initials: Z
authors.lastname: Lian
authors.forename: Y
authors.initials: Y
authors.lastname: Cui
authors.forename: J
authors.initials: J
authors.lastname: Toki
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Jin
authors.forename: T
authors.initials: T
authors.lastname: Fan
authors.forename: G
authors.initials: G
authors.lastname: Yang
authors.forename: C
authors.initials: C
authors.lastname: Yu
authors.forename: T
authors.initials: T
authors.lastname: Kushida
authors.forename: S
authors.initials: S
authors.lastname: Ikehara
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000276:immunology; D000954:Antigens, Surface; D015415:Biomarkers; D002454:Cell Differentiation; D019070:Cell Lineage; D002478:Cells, Cultured; D016207:Cytokines / Q000276:immunology / Q000494:pharmacology; D003713:Dendritic Cells / Q000166:cytology* / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D051379:Mice; D008810:Mice, Inbred C57BL; D019009:Proto-Oncogene Proteins c-kit
chemical_list: D015703:Antigens, CD; D000954:Antigens, Surface; D015415:Biomarkers; D016207:Cytokines; D019009:Proto-Oncogene Proteins c-kit